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Abstract
We evaluated the efficiency and toxicity of estramustine phosphate (ECT), ifosfamide (IFM)
and cisplatin (CDDP) combination chemotherapy in twenty-one patients with hormone-refractory
prostate cancer (HRPC), for which there is currently no effective treatment. Patients received a
daily dose of 560 mg ECT in combination with 1.2 g/m2 IFM on days 1 to 5 and 70 mg/m2 CDDP
on day 1. This combination therapy was given every 3 to 4 weeks. An objective response of
more than 50% reduction in prostate-specific antigen was observed in 9 of 18 patients (50%), and
a more than 50% reduction in bi-dimensionally measurable soft-tissue lesions was observed in 2
of 7 patients (29%). The median duration of response among the cases showing partial response
was 40 weeks, while the median duration of response of overall partial-response plus stable cases
was 30 weeks. The median survival duration of all cases was 47 weeks. Toxicity was modest
and acceptable. In conclusion, the ECT, IFM and CDDP combination chemotherapy regimen is
a viable treatment option for HRPC. However, in comparison with our previous chemotherapy
regimen of IFM and CDDP, no additional long-lasting effects resulting from the inclusion of ECT
could be affirmed.
KEYWORDS: hormone-refractory prostate cancer, chemotherapy, estramustine phosphate, ifos-
famide, cisplatin
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ndrogen ablation and secondary hormonal 
maneuvers are eﬀ ective in treating metastatic 
prostate cancer,  but there are limited options for the 
treatment of hormone-refractory disease.  To date, 
chemotherapy has been shown to improve quality of 
life but not survival in symptomatic patients [1,  2]. 
There is still no standard treatment for the many 
patients with hormone-refractory disease and a simul-
taneous rise in prostate-speciﬁ c antigen (PSA) or 
radiological progression.  Even though a rise in PSA 
is a harbinger of clinical metastatic disease,  the 
median survival from development of hormone-refrac-
tory disease to death is only several months [3].  In 
our previous study,  which combined ifosfamide (IFM) 
and cisplatin (CDDP) (IP therapy),  IP therapy was 
shown to have consistent eﬀ ects,  but the necessity of 
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devising a more potent chemotherapy with longer-
lasting activity was also recognized [4].  According 
to a study that compared vinblastine (VLB) mono-
therapy with combined VLB ＋ ECT therapy,  ECT 
appeared useful : time to progression was prolonged 
and the percentage of cases exhibiting 50ｵ or 
greater reduction in PSA was signiﬁ cantly higher in 
the combined therapy group [5].  Based on these 
ﬁ ndings,  we undertook the present study to examine 
the eﬃ  cacy and safety of a 3-drug combination chemo-
therapy (EIP therapy) involving ECT,  IFM and 
CDDP.
Patients and Methods
　　Patients were considered eligible for this study if 
they had progressive prostate cancer deﬁ ned by 2 or 
more serial increases of PSA values of at least 4 ng/
ml obtained at least 2 weeks apart,  or progressive 
radiological disease,  following androgen ablation,  an 
antiandrogen,  and antiandrogen withdrawal.  Patients 
were also required to meet the following criteria : (1) 
well-preserved functioning of major organs 
(Hb ＞ 9.0 g/dl,  WBC ＞ 4000/mm3,  GOT and GPT ＜ 
twice the normal level,  total bilirubin ＜ 1.5 mg/dl, 
serum creatinine ＜ 2.0 mg/dl,  and creatinine clear-
ance ＞ 50 ml/min) ; (2) a performance status (PS) 
between 0 and 3 ; (3) age between 20 and 75 
years ; (4) a survival expectancy of at least 3 
months ; and (5) provision of written informed con-
sent.  Patients were excluded from this study if (1) 
they had been treated previously with ECT,  IFM or 
CDDP ; (2) they had received radiotherapy within 8 
weeks before initiation of this study ; (3) they had 
serious complications ; or (4) they had active double 
cancer.  The clinical protocol was approved by the 
Okayama University Hospital Clinical Trials Review 
Committee,  and by the relevant institutional review 
boards.
　　EIP therapy was administered according to the 
following schedules.  ECT was orally administered 
every day at a dose of 560 mg/day ; IFM was admin-
istered intravenously (1.2 g/m2) on days 1 through 
5 ; and CDDP was administered intravenously (70 mg/
m2) on day 1.  The administrations of IFM and CDDP 
were repeated for each cycle every 3 weeks. 
Thereafter,  ECT was administered continuously as a 
maintenance therapy.
　　The eﬀ ects of this treatment were evaluated 
according to the General Rules for Surgical and 
Pathological Studies on Prostate Cancer (3 rd edition) 
[6].  Survival rate was calculated using the Kaplan-
Meier method.
　　Adverse reactions were reported in accordance 
with the nomenclature used in the Criteria for 
Evaluation of Reinforced Eﬃ  cacy of Chemotherapy for 
Solid Cancer, prepared by the Japan Society of 
Clinical Oncology.
Results
　　Background factors (Table 1) : Twenty-two 
patients with hormone-refractory prostate cancer 
(HRPC) who received treatment at our institution 
between August 1995 and August 2001 were enrolled 
in this study.  Twenty-one of these patients were 
included in the ﬁ nal subject group,  with 1 patient 
who received radiotherapy during EIP therapy being 
excluded.  Prior therapies consisted of hormonal 
therapy (n ＝ 15 patients),  chemotherapy (n ＝ 2), 
radiotherapy for the prostate gland (n ＝ 3),  and 
radiotherapy for the lumbar vertebrae (n ＝ 1).
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Table 1　　Patient Characteristics ― Comparison with IP 
Chemotherapy ―
 IP (n ＝ 27) EIP (n ＝ 21)
Age (y.o.) 60ﾝ77 (Median67) 51ﾝ79 (Median66)
Performance status 0 7 8
 1 11 11
 2 6 1
 3 1 1
 4 2 0
Stage C 2 1
 D1 1 0
 D2 24 20
Grade well 1 0
 mod 13 8
 por 12 13
Measurable Disease
　Lymph Nodes  7 7
　Breast  0 1
　Lung  2 0
Prior Therapy
　Hormonal only  7 15
　Hormonal ＋ chemotherapy 14 2
　Horomonal ＋ radination 6 4
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　　In our previous study,  on the other hand,  the sub-
ject group consisted of 27 patients who received IP 
therapy for HRPC between January 1990 and May 
1995,  and only 7 patients had received prior hor-
monal therapy,  while 14 and 6 had received prior 
chemotherapy or radiotherapy,  respectively.
　　Dose level : EIP therapy was administered for 1 
to 4 cycles (median : 3 cycles).  Sixteen patients 
received 2 or more cycles.  Five patients received 
only 1 cycle because of general fatigue and gastroin-
testinal symptoms (n ＝ 1),  renal dysfunction (n ＝ 1), 
myocardial infarction (n ＝ 1),  or severe bone marrow 
suppression (n ＝ 2).
　　Response (Table 2) : The locations of the lesions 
were as follows : PSA (n ＝ 18),  prostate (n ＝ 16), 
bone (n ＝ 14),  lymph nodes (n ＝ 7) and mammary 
glands (n ＝ 1).  Seventeen cases had more than one 
location : PSA ＋ bone (n ＝ 10) ; PSA ＋ lymph nodes 
(n ＝ 5) ; PSA ＋ bone ＋ lymph nodes (n ＝ 2) ; and 
PSA ＋ bone ＋ mammary glands (n ＝ 1).  A 50ｵ or 
greater decrease in PSA response was recognized in 
9 (50ｵ) of the 18 patients.  In the measurable 
lesions,  2 of the 7 patients (29ｵ) with lymph node 
metastasis and the patient with breast metastasis 
showed 50ｵ or more reduction.  The primary lesion 
remained stable in 13 (81ｵ) of the 16 patients, 
whereas 3 patients (19ｵ) showed progression.  In 
addition,  evaluation of bone metastasis by bone scin-
tigraphy revealed a marked decrease in radioactivity 
uptake in 2 of 14 patients.
　　The overall patient response rate was PR (partial 
response) in 3 (15ｵ),  NC (no change) in 11 (52ｵ, 
including 7 stable cases),  and PD (progressive dis-
ease) in 7 (33ｵ) patients.  The percentage of 
PR ＋ stable cases,  which is described as an impor-
tant parameter in the General Rules for Surgical and 
Pathological Studies on Prostate Cancer,  was 33ｵ 
in this study [6].
　　In IP therapy,  a 50ｵ or greater decrease in 
PSA response was recognized in 7 (30ｵ) of the 21 
patients.  In the measurable lesions,  3 of the 7 
patients (43ｵ) with lymph node metastasis showed 
50ｵ or more reduction,  But no response in the 
patient with lung metastasis.  The primary lesion 
remained stable in 16 (89ｵ) of the 18 patients, 
whereas 2 patients (11ｵ) showed progression.
　　In the 3 patients with PR,  anti-tumor eﬀ ects 
remained for 18 to 90 weeks (median progression-
45EIP chemotherapy for HRPCFebruary 2006
Table 2　　Response Status of EIP Chemotherapy ― Comparison with IP Chemotherapy ―
2a Response Status of IP Chemotherapy
  CR PR NC [ST] PD
Prostate (N ＝ 18) 0 ( 0%) 3 (17%) 13 ( 72%) 2 (11%)
Bone (N ＝ 17) 0 ( 0%) 1 ( 6%) 14 ( 82%) 2 (12%)
Lymph node (N ＝  7) 1 (14%) 2 (29%) 3 ( 43%) 1 (14%)
Lung (N ＝  2) 0 ( 0%) 0 ( 0%) 1 (100%) 0 ( 0%)
PSA (N ＝ 21) 4 (19%) 3 (14%) 9 ( 43%) 5 (24%)
Total (N ＝ 27) 0 ( 0%) 7 (26%) 13 (48%) (10 (37%)) 7 (26%)
2b Response Status of EIP Chemotherapy
  PR NC [ST] PD
Prostate (N ＝ 16) 0 (  0%) 13 (81%) 3 (19%)
Bone (N ＝ 14) 2 ( 14%) 9 (65%) 3 (21%)
Lymph node (N ＝  7) 2 ( 29%) 2 (29%) 3 (42%)
Breast (N ＝  1) 1 (100%) 0 ( 0%) 0 ( 0%)
PSA (N ＝ 18) 9 ( 50%) 8 (44%) 1 ( 6%)
Total (N ＝ 21) 3 ( 15%) 11 (52%) (7 (33%)) 7 (33%)
PR,  partial response ; NC,  no change ; ST,  stable disease ; PD,  progressive disease
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free survival period ＝ 40 weeks).  On the other hand, 
in the 7 patients with PR ＋ stable cases,  anti-tumor 
eﬀ ects remained for 16 to 165 weeks (median pro-
gression-free survival period ＝ 30 weeks).  For the 
entire series,  the median progression-free survival 
period was 16 weeks.  The 3-year survival rate was 
13ｵ,  and the median survival duration was 47 weeks 
(Fig.  1).  The median progression-free survival 
period was 21 weeks.  The 3-year survival rate was 
36ｵ,  and the median survival duration was 92 weeks 
in IP therapy.
　　The anti-tumor response of EIP therapy was 
assessed with background factors.  When considering 
histological diﬀ erentiation of cancer cells,  the 
response was PR in 2,  and NC in 4 of the 8 patients 
with moderaPhoney-diﬀ erentiated cancer.  Of the 13 
patients with poorly-diﬀ erentiated cancer,  1 was PR 
and 7 were NC (stable cases in 4 patients).  Of the 15 
patients who had received endocrine therapy alone 
prior to EIP therapy,  1 PR and 9 NC (3 stable 
cases) were observed.  Of the 6 patients who under-
went tegaful-based therapy or radiotherapy,  2 PR 
and 2 NC (1 stable case) were observed.  As for sub-
jective symptoms,  there was a decrease in pain and 
an improvement in voiding disorder in 6 (29ｵ) of the 
21 cases.  The adverse reactions are shown in Table 3. 
As subjective adverse reactions,  nausea and vomiting 
were frequently noted (67ｵ).  Alopecia was observed 
in 48ｵ of all patients.  Hematologically,  bone mar-
row suppression was frequently noted.  Anemia was 
observed in 16 (76ｵ) of the 21 patients.  Among the 
patients with anemia,  29ｵ were rated as grade 3, 
and 3 patients required red blood cell transfusions. 
Leukocytopenia was noted in 12 (57ｵ) of the 21 
patients,  with the percentage of patients with grade 
3 leukocytopenia being 19ｵ.  Neutrophil counts were 
below 500/mm3 in 2 patients and concomitant G-CSF 
administrations were required in 4. 
Thrombocytopenia was noted in 10 (48ｵ) of the 21 
patients,  and was grade 3 in 14ｵ.  Platelet transfu-
sions were required in 2 cases.  Biochemically,  liver 
dysfunction was noted in 4 patients (19ｵ),  including 
2 patients with grade 3 ﬁ ndings,  and renal dysfunc-
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Fig. 1　　A: Cause-speciﬁ c survival and progression-free survival 
of IP.  The median progression-free survival period was 21 weeks. 
The 3-year survival rate was 36%,  and the median survival 
duration was 92 weeks.
B: Cause-speciﬁ c survival and progression-free survival of EIP.
The median progression-free survival period was 16 weeks.  The 
3-year survival rate was 13%,  and the median survival duration 
was 47 weeks.
Table 3　　Toxicity of EIP Chemotherapy (n ＝ 21) ― Comparison 
with IP Chemotherapy (n ＝ 27) ―
 Incidence (%) Grade 3  (%)
 IP EIP IP EIP
Nausea/Vomiting 20 (74%) 14 (67%) 4 (15%) 1 ( 5%)
Alopecia 18 (67%) 10 (48%) ﾝ ﾝ
Anemia 20 (96%) 16 (76%) 3 (12%) 6 (29%)
Leukocytopenia 24 (89%) 12 (57%) 9 (33%) 4 (19%)
Thrombocytopenia 6 (22%) 10 (48%) 2 ( 7%) 3 (14%)
Hepatic toxicity 2 ( 7%) 4 (19%) 0 ( 0%) 2 (10%)
Renal toxicity 5 (19%) 5 (24%) 1 ( 4%) 0 ( 0%)
4
Acta Medica Okayama, Vol. 60 [2006], Iss. 1, Art. 5
http://escholarship.lib.okayama-u.ac.jp/amo/vol60/iss1/5
tion was noted in 5 patients (24ｵ).  All of these 
abnormalities subsided following treatment,  except 
in 1 patient in whom marked liver dysfunction was 
noted and bone marrow suppression prompted discon-
tinuation of therapy after one cycle.  Deep venous 
thrombosis was observed in 1 patient,  and myocar-
dial infarction developed in another.
Discussion
　　At present,  there is no widely accepted method of 
treatment for hormone-refractory prostate cancer. 
We previously conducted combined IFM ＋ CDDP 
chemotherapy (IP therapy) for 27 patients with 
advanced prostate cancer.  In that study,  the period 
of eﬃ  cacy was short,  suggesting the necessity of 
devising a more potent chemotherapy [4].  In the 
present study,  we attempted EIP therapy,  adding 
ECT to IP therapy.  ECT is a drug produced by car-
bamate binding of estradiol to nitrogen mustard. 
Because degradation of ECT releases estrogen, 
keeping the blood testosterone level in the castration 
range,  combined use of LH-RH agonist is unneces-
sary.  The rate of response to ECT therapy is about 
90ｵ in untreated fresh cases,  but is as low as about 
20ｵ in hormone-refractory cases [7].  Attempts 
have been made to use ECT in combination with one 
or more of vinblastine,  paclitaxel,  docetaxel,  etopo-
side,  etc.  [8ﾝ19].
　　In a study that compared ECT ＋ VLB combina-
tion therapy with VLB monotherapy in 192 patients 
[5],  the percentage of patients with 50ｵ or greater 
decrease in PSA was signiﬁ cantly higher in the 
ECT ＋ VLB group (40ｵ) than in the VLB group (5
ｵ).  The 50ｵ progression-free survival period was 
signiﬁ cantly longer in the ECT ＋ VLB group (3.7 
months) than in the VLB group (2.1 months) (p
＜ 0.001).  When adverse reactions were analyzed in 
that study,  the incidences of queasiness and edema 
were signiﬁ cantly higher in the combined therapy 
group than in the monotherapy group.  The severity 
of granulocytopenia was signiﬁ cantly lower in the 
combined therapy group,  suggesting that ECT can 
suppress VLB-induced granulocytopenia.
　　In the present study,  the percentage of patients 
with 50ｵ or greater decrease in PSA following EIP 
therapy was 50ｵ,  whereas only 33ｵ of patients 
achieved such a decrease by IP therapy in our previ-
ous series.  Thus,  the concomitant administration of 
ECT may enhance early response.  However,  the 
median progression-free survival period was 40 
weeks for the 3 patients with PR to EIP therapy and 
30 weeks for the 7 patients with PR ＋ stable cases. 
Conversely,  of the patients treated with IP therapy, 
the median progression-free survival period was 69 
weeks for the 7 with PR and 43 weeks for the 7 with 
PR ＋ stable cases.  There had a complete respone in 
1 (14ｵ) with lymph node,  4 (19ｵ) on PSA from the 
IP therapy,  But no one from EIP therapy.  The 
median progression-free survival period and the 
47EIP chemotherapy for HRPCFebruary 2006
Table 4　　Estramustine Phosphate (ECT) Based Chemotherapy
Regimen Author No. of No. (%) with PSA No. (%) with CR/PR in Median  Pts. Decrease 50% Measurable Disease Survival
ECT ＋ vinblastine Seidman[8] 25 13/24 (54%) 2/5 (40%) 7 months
 Hudes[9] 40 22/36 (61%) 1/7 (14%) 48 weeks
 Hudes[5] 95 35/87 (40%) 6/30 (20%) 48 weeks
ECT ＋ paclitaxel Hudes[10] 34 17/32 (53%) 4/9 (44%) 69 weeks
 Haas[11] 24 9/24 (37%) 6/13 (46%) 18.9 months
ECT ＋ paclitaxel ＋ etoposide Smith[12] 40 26/40 (65%) 10/22 (45%) 13 months
ECT ＋ paclitaxel ＋ carboplatin Kelly[13] 56 40/56 (67%) 19/33 (45%) 19.9 months
ECT ＋ docetaxel Kreis[14] 17 14/17 (82%) ﾝ (16%) ﾝ
 Petrylak[15] 34 20/32 (63%) 5/18 (28%) ﾝ
ECT ＋ docetaxel ＋ hydrocortisone Savarese[16] 47 30/44 (68%) 12/24 (50%) 20 months
ECT ＋ etoposide Pienta[17] 62 24/62 (39%) 8/15 (53%) 56 weeks
 Dimopoulos[18] 56 30/51 (59%) 15/33 (45%) 52 weeks
ECT ＋ doxorubicin Culine[19] 31 18/31 (58%) 5/11 (45%) 48 weeks
ECT ＋ IFM ＋ CDDP Kaku 21 9/18 (50%) 2/7 (29%) 47 weeks
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median survival duration were shorter for EIP ther-
apy (16 and 47 weeks,  respectively) than for IP ther-
apy (21 weeks and 92 weeks).
　　We could not conﬁ rm that addition of ECT 
yielded any additional long-lasting eﬀ ects,  although 
diﬀ erences in background between these treatment 
groups might exist.  In addition,  the current study 
obtained compatible but not superior results in early 
response and survival in comparison to several previ-
ous studies employing multiple drug therapies that 
included ECT (Table 4) [5,  9ﾝ19].
　　A Subjective symptoms,  were alleviated in 29ｵ 
and remained unchanged in 52ｵ of all cases follow-
ing EIP therapy and were similar to those following 
IP therapy,  where symptoms were alleviated in 41ｵ 
and remained unchanged in 41ｵ.When adverse reac-
tions were compared between the EIP and the IP 
therapy groups (Table 3),  the incidence of gastroin-
testinal symptoms in the EIP therapy group (67ｵ) 
did not increase compared to that in the IP therapy 
group (74ｵ).  Myelosupression was also comparable 
to that observed with IP therapy.  One patient from 
the EIP therapy group developed deep venous throm-
bosis,  and another exhibited myocardial infarction. 
These 2 cases indicate the need for care in monitor-
ing for coagulation and vascular occlusion with EIP 
therapy.
　　Unfortunately,  EIP therapy demonstrated no 
obvious advantages over IP therapy in this study.  In 
the treatment of HRPC,  the necessity for long-last-
ing activity remains.  A new regimen that includes a 
multi-descriptional approach should be developed, 
such as a combined immunogene therapy which can be 
switched to maintenance therapy.
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